Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.
Animals
Carcinoma, Pancreatic Ductal
/ drug therapy
Cell Line, Tumor
DNA Damage
Enzyme Inhibitors
/ pharmacology
Female
Gene Silencing
Glycoside Hydrolases
/ antagonists & inhibitors
Humans
Mice, Nude
Molecular Targeted Therapy
Oxaliplatin
/ pharmacology
Pancreatic Neoplasms
/ drug therapy
Recombinational DNA Repair
Small Molecule Libraries
/ pharmacology
Xenograft Model Antitumor Assays
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 09 2019
01 09 2019
Historique:
received:
20
11
2018
revised:
06
05
2019
accepted:
01
07
2019
pubmed:
6
7
2019
medline:
17
6
2020
entrez:
6
7
2019
Statut:
ppublish
Résumé
Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than 1 year, underscoring the importance of evaluating novel targets with matched targeted agents. We recently identified that poly (ADP) ribose glycohydrolase (PARG) is a strong candidate target due to its dependence on the pro-oncogenic mRNA stability factor HuR (
Identifiants
pubmed: 31273064
pii: 0008-5472.CAN-18-3645
doi: 10.1158/0008-5472.CAN-18-3645
pmc: PMC6816506
mid: NIHMS1533920
doi:
Substances chimiques
Enzyme Inhibitors
0
Small Molecule Libraries
0
Oxaliplatin
04ZR38536J
Glycoside Hydrolases
EC 3.2.1.-
poly ADP-ribose glycohydrolase
EC 3.2.1.143
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4491-4502Subventions
Organisme : Cancer Research UK
ID : C480/A11411
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C5759/A17098
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA212600
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA227865
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA056036
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Minerva Ginecol. 2018 Apr;70(2):150-170
pubmed: 28994564
Gastroenterology. 2004 Jul;127(1):250-60
pubmed: 15236190
Mol Cell Biochem. 1999 Mar;193(1-2):19-22
pubmed: 10331633
Int J Cancer. 2018 Jul 1;143(1):179-183
pubmed: 29396858
J Vis Exp. 2011 Mar 13;(49):null
pubmed: 21445039
Breast Cancer Res Treat. 2011 May;127(1):283-6
pubmed: 21301956
Oncotarget. 2015 Sep 29;6(29):27312-31
pubmed: 26314962
Nat Commun. 2013;4:2164
pubmed: 23917065
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
Pathol Oncol Res. 2012 Apr;18(2):191-9
pubmed: 21713600
Cell Death Dis. 2013 Jun 06;4:e656
pubmed: 23744356
Carcinogenesis. 2010 Dec;31(12):2058-65
pubmed: 20926829
Exp Hematol Oncol. 2015 Oct 07;4:29
pubmed: 26451276
Genome Med. 2013 Aug 31;5(8):78
pubmed: 24004612
Clin Cancer Res. 2018 Oct 15;24(20):5018-5027
pubmed: 29954777
Oncogene. 2016 May;35(19):2529-41
pubmed: 26387536
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17699-704
pubmed: 15591342
Cancer Lett. 2015 Jul 10;363(1):1-6
pubmed: 25890222
World J Gastroenterol. 2014 Jun 28;20(24):7849-63
pubmed: 24976722
Oncotarget. 2016 Feb 23;7(8):9477-90
pubmed: 26843614
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Hum Mutat. 2017 Feb;38(2):226-235
pubmed: 27767231
Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):385-90
pubmed: 26543084
DNA Repair (Amst). 2017 Apr;52:81-91
pubmed: 28254358
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Br J Cancer. 2017 Apr 11;116(8):1021-1026
pubmed: 28291774
Biomed Rep. 2017 Nov;7(5):391-399
pubmed: 29109859
Nat Commun. 2019 Mar 12;10(1):1182
pubmed: 30862789
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Cancer Discov. 2018 Sep;8(9):1096-1111
pubmed: 29903880
J Clin Med. 2019 Mar 30;8(4):null
pubmed: 30934991
Cancer Res. 2008 Jul 1;68(13):5023-30
pubmed: 18593900
Cancer Res. 2017 Sep 15;77(18):5011-5025
pubmed: 28687616
Oncology (Williston Park). 2017 Mar 15;31(3):159-66, 168
pubmed: 28299752
Eur J Cancer. 2018 Jan;89:19-26
pubmed: 29223478
J Cell Sci. 2009 Jun 15;122(Pt 12):1990-2002
pubmed: 19454480
Genes Dev. 2005 Sep 1;19(17):1951-67
pubmed: 16140981
Cancer Discov. 2013 Jan;3(1):20-3
pubmed: 23319766
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Biochem Biophys Res Commun. 2013 Nov 29;441(4):793-8
pubmed: 24211580
DNA Repair (Amst). 2018 Jan;61:25-36
pubmed: 29179156
Expert Opin Ther Pat. 2013 Apr;23(4):503-14
pubmed: 23379721
Clin Cancer Res. 2014 Oct 1;20(19):5085-96
pubmed: 25117293
Oncotarget. 2016 Jan 19;7(3):2765-79
pubmed: 26624983
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12
pubmed: 29894693
Front Pharmacol. 2017 Apr 20;8:158
pubmed: 28473769
Nucleic Acids Res. 2015 Aug 18;43(14):6934-44
pubmed: 26130715
Mol Cell Biol. 2001 Jun;21(12):4032-45
pubmed: 11359910
Oncotarget. 2018 Apr 20;9(30):21613-21627
pubmed: 29765563
Gastroenterology. 2006 Jun;130(7):2145-54
pubmed: 16762635
Cancer Discov. 2017 Jun;7(6):620-629
pubmed: 28242752
Mol Cell Biol. 2004 Aug;24(16):7163-78
pubmed: 15282315
Cell Cycle. 2005 Mar;4(3):397-9
pubmed: 15725727
Science. 2008 Sep 26;321(5897):1801-6
pubmed: 18772397
Bioinformatics. 2016 Sep 15;32(18):2866-8
pubmed: 27153664
Cancer Res. 2014 Feb 15;74(4):1128-40
pubmed: 24536047
ACS Chem Biol. 2016 Nov 18;11(11):3179-3190
pubmed: 27689388
Gastroenterol Res Pract. 2019 Feb 4;2019:7690528
pubmed: 30863442
J Med Chem. 2018 Dec 13;61(23):10767-10792
pubmed: 30403352